GPP
CNST

Great Point Partners’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Great Point Partners’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-872,415
Closed -$20.4M – 40
2021
Q1 		$20.4M Sell
872,415
-152,385
-15% -$4.62M 4.22% 13
2020
Q4 		$29.5M Sell
1,024,800
-1,837,124
-64% -$46.2M 4.79% 8
2020
Q3 		$58M Sell
2,861,924
-618,076
-18% -$15.1M 5.22% 7
2020
Q2 		$105M Buy
3,480,000
+1,502,498
+76% +$54.1M 8.36% 1
2020
Q1 		$62.2M Buy
1,977,502
+842,380
+74% +$29.3M 6.49% 5
2019
Q4 		$53.5M Buy
+1,135,122
New +$32.8M 4.66% 9

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Great Point Partners's CNST Position: Q2 2021 in Review

Great Point Partners sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 872,415 shares — an estimated $20.4M sold.

Great Point Partners first reported a position in CNST in Q4 2019 and held it in 6 quarters. The position peaked at $105M in Q2 2020. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Great Point Partners reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Great Point Partners sold 872,415 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $20.4M.
  • Great Point Partners first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
  • Great Point Partners's Constellation Pharmaceuticals, Inc. position peaked at $105M in Q2 2020.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Great Point Partners's 13F filing for Q2 2021, filed 16 Aug 2021.